Neurotech Partners
Neurotech

イベントの概要

この学会は、脳や神経系の新たな治療法や診断法の開発に携わっている投資家、起業家、企業幹部、研究者などが一堂に会し、所属する組織と業界の将来について考える国際的なフォーラムです。

会期中は、ニューロテクノロジー業界の最新動向に関する基調講演、企業による最先端技術の発表、主なトランスレーショナル研究プロジェクトについての報告、パネルディスカッションなどが予定されており、ニューロテクノロジー関連のトピックを幅広く網羅します。

PRELIMINARY AGENDA


5月31日 (水)


7:30 登録手続き、朝食

8:30 基調講演、2017年のニューロテクノロジー業界の状況
Alison Fenney, Executive Director, Neurotechnology Industry Organization
Harry Tracy, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports

9:00 ニューロテクノロジー分野への投資に関するパネルディスカッション
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Josh Pinto, Vice President, CNS, Credit Suisse

Panelists: Andy Schwab, Managing Partner, 5AM Ventures
Joseph Sum, Analyst, EcoR1 Capital
Ilan Zipkin, Senior Investment Director, Takeda Venture Partners
Heath Lukatch, Partner and Managing Director, TPG Biotech

10:00 展示会ホールでの休憩、ポスター発表の見学

10:40 アルツハイマー病と認知症の治療
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?

Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix

11:40 神経障害性疼痛とてんかんに対する治療法の開発動向
Ongoing research is revealing new pharmaceutical and device options to treat pain and epilepsy. Novel therapeutic modalities aim to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. What are the novel devices in this space? How are side effects being addressed?

Panelists: Alex Ni, CTO, Avertus
Alan Mock, Chief Commercial Officer, Algostim

12:40 昼食会

13:55 組織内外での研究開発
Big pharma, big medtech and large biotech companies collaborate with smaller companies and academic institutions on a variety of projects. How can opportunities be spotted? What are current areas of interest? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?
Moderator: Jay Kranzler, CEO, Regenovation

Panelists: Ryan Westphal, Director, Search and Evaluation, Neuroscience, Eli Lilly and Company
Thorsten Melcher, Senior Director, New Ventures, Johnson & Johnson Innovation
Anne Pianca, Director, R&D Neuromodulation, Boston Scientific
Rivka Kreitman, Senior Vice President & Head, Global Search and Evaluation, Teva Pharmaceuticals

14:55 展示会ホールでの休憩、ポスター発表の見学

15:35 中枢神経系疾患に対応する薬剤と機器の開発に向けた戦略
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Panelist: Tina Soulis, General Manager, Neuroscience Trials Australia

16:35 新興企業の紹介
Submissions to be accepted in February

17:35 展示会ホールでの歓迎レセプション、ポスター発表の見学

18:30 1日目終了


6月1日 (木)


7:30 登録手続き、朝食

8:30 ニューロテクノロジー分野でのライセンスと買収
Neurology is projected to be medtech's fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. Overall all, big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? What are priority indications and requirements for licensing deals? Which companies are active in deal-making?
Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises

Panelists: Susan Lin, Vice President, New Ventures & Business Development, LivaNova
Jeff Calcagno, New Ventures, Johnson & Johnson Innovation

9:30 パーキンソン病などの運動障害
Current treatments for movement disorders can improve functioning but suffer from side effects and "off" period especially as the disease progresses. What are the latest advances in movement disorders? What is in the pipeline to address side effects and other issues specific to this class? Can disease modifying treatments alter the course of disease? Can diagnostics improve treatment?
Moderator: John Reppas, Director, Public Policy, Neurotechnology Industry Organization

Panelist: Kyle Gano, Vice President, Business Development, Neurocrine Biosciences

10:30 展示会ホールでの休憩、ポスター発表の見学

11:15 次世代の精神医学
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next-generation treatments? How will devices and diagnostics change the treatment landscape?
Moderator: Manuel Lopez Figueroa, Partner, Bay City Capital

Panelists: Yaron Daniely, President & CEO, Alcobra
Robert Linke, President & CEO, Embera NeuroTherapeutics

12:15 昼食会

13:30 ニューロテクノロジー分野の未開拓領域
In this session we will hear from companies on the cutting edge. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Which are the most exciting next-generation products and companies? How are they addressing unmet needs in neurotech?
Moderator: Imran Eba, Partner, Action Potential Venture Capital, GSK

Panelists: Corianna Lathan, CEO, Anthrotronix
Laura Tyler Perryman, CEO and Co-Founder, StimWave
Will Rosellini, CEO, Nexeon Medi

14:30 神経治療栄養学
Nutrition is at the core of novel approaches for disease prevention and treatments. What is neurotherapeutic nutrition? How can nutrition address CNS disorders? What companies are focusing on developing neurotherapeutic nutrition approaches? What hurdles will these companies face?
Moderator: Bram Goorden, Vice President, Global Head, Nestle Health Science

Panelists: John Andrews, CEO, Ketogen
Joan Fallon, CEO, Curemark
Jill C. Milne, CEO, Catabasis

15:30 休憩

15:45 希少疾患の標的化
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. Hear from companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more. What are the strategies to succeed in addressing a smaller market? Are R&D approaches different than for other indications?

Panelist: Tim Miller, CEO, Abeona Therapeutics

16:45 多発性硬化症治療の新たな戦略
Therapies directed at novel targets, more specific immune modulators and trophic factors are in development for multiple sclerosis. What are the promising treatments in development? How are indication-specific hurdles being addressed? What novel approaches are being pursued?

Panelists: Maurice Zauderer, CEO, Vaccinex
Marie Wesselhoft, President and Co-Founder, MSDx

17:45 学会閉幕

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

カタログ(PDF)
Demographics

 NIO


 

View All Sponsors